These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 8342582

  • 1. Treatment of severe secondary hyperparathyroidism with administration of calcium carbonate, intermittent high oral doses of 1,25-dihydroxyvitamin D3 and dialysate with 3 mEq/1 calcium concentration.
    Perez-Mijares R, Gomez-Fernandez P, Almaraz-Jimenez M, Ramos-Diaz M, Rivero-Bohorquez J.
    Am J Nephrol; 1993; 13(2):149-54. PubMed ID: 8342582
    [Abstract] [Full Text] [Related]

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L.
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [Abstract] [Full Text] [Related]

  • 3. The 'oral 1,25-dihydroxyvitamin D3 pulse therapy' in hemodialysis patients with severe secondary hyperparathyroidism.
    Tsukamoto Y, Nomura M, Takahashi Y, Takagi Y, Yoshida A, Nagaoka T, Togashi K, Kikawada R, Marumo F.
    Nephron; 1991 Nov; 57(1):23-8. PubMed ID: 2046811
    [Abstract] [Full Text] [Related]

  • 4. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients.
    Slatopolsky E, Weerts C, Thielan J, Horst R, Harter H, Martin KJ.
    J Clin Invest; 1984 Dec; 74(6):2136-43. PubMed ID: 6549016
    [Abstract] [Full Text] [Related]

  • 5. Suppression of secondary hyperparathyroidism in chronic dialysis patients by single oral weekly dose of 1,25-dihydroxycholecalciferol.
    Shigematsu T, Kawaguchi Y, Unemura S, Yamamoto H, Momose M, Yokoyama K, Wakabayashi Y, Ikeda M, Hasegawa T, Sakai O.
    Intern Med; 1993 Sep; 32(9):695-701. PubMed ID: 8142673
    [Abstract] [Full Text] [Related]

  • 6. Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients. Durham Renal Osteodystrophy Study Group.
    Indridason OS, Quarles LD.
    Kidney Int; 2000 Jan; 57(1):282-92. PubMed ID: 10620210
    [Abstract] [Full Text] [Related]

  • 7. Treatment of secondary hyperparathyroidism in hemodialyzed patients with high-dose calcium carbonate without vitamin D3 supplements.
    Teruel JL, Tenorio MT, Rodríguez JR, Marc n R, Orofino L, Rivera M, Ortuño J.
    Am J Nephrol; 1999 Jan; 19(3):428-32. PubMed ID: 10393383
    [Abstract] [Full Text] [Related]

  • 8. Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD.
    Quarles LD, Yohay DA, Carroll BA, Spritzer CE, Minda SA, Bartholomay D, Lobaugh BA.
    Kidney Int; 1994 Jun; 45(6):1710-21. PubMed ID: 7933819
    [Abstract] [Full Text] [Related]

  • 9. Oral 1,25(OH)2D3 pulse therapy for the treatment of secondary hyperparathyroidism.
    Takahashi S, Okada K, Kinosita Y, Yanai M, Kuno T, Nagura Y.
    Nihon Jinzo Gakkai Shi; 1993 Apr; 35(4):377-82. PubMed ID: 8341016
    [Abstract] [Full Text] [Related]

  • 10. 'Pulse oral' versus intravenous calcitriol therapy in chronic hemodialysis patients. A prospective and randomized study.
    Bacchini G, Fabrizi F, Pontoriero G, Marcelli D, Di Filippo S, Locatelli F.
    Nephron; 1997 Apr; 77(3):267-72. PubMed ID: 9375818
    [Abstract] [Full Text] [Related]

  • 11. [Long-term treatment with large doses of alphacalicidol in secondary hyperparathyroidism of patients dialyzed for end stage renal failure].
    Matuszkiewicz-Rowińska J, Niemczyk S, Pacocha E, Puka J, Switalski M, Bogdańska-Straszyńska B, Ostrowski K.
    Pol Arch Med Wewn; 1996 Jul; 96(1):15-22. PubMed ID: 8966141
    [Abstract] [Full Text] [Related]

  • 12. A crossover comparison of intermittent oral and intravenous administration of calcitriol on the parathyroid hormone concentration in hemodialysis patients.
    Peng SJ, Yang CS, Ferng SH, Chen LY.
    Miner Electrolyte Metab; 1997 Jul; 23(1):13-8. PubMed ID: 9058364
    [Abstract] [Full Text] [Related]

  • 13. [The oral 1-25 dihydroxyvitamin D3 pulse therapy in hemodialysis patients for the early treatment of secondary hyperparathyroidism].
    Kawabe M, Shimizu M, Takeuchi M, Matsunobu S, Hayama N, Iino Y, Hara K, Terashi A.
    Nihon Jinzo Gakkai Shi; 1992 Jul; 34(7):807-11. PubMed ID: 1479720
    [Abstract] [Full Text] [Related]

  • 14. [A trial of suppressing secondary hyperparathyroidism by oral high dose therapy of 1, 25-dihydroxyvitamin D3].
    Shigematsu T, Kawaguchi Y, Unemura S, Suzuki M, Yamamoto H, Morita T, Momose M, Ogawa A, Nakayama M, Miyahara T.
    Nihon Jinzo Gakkai Shi; 1989 Apr; 31(4):393-401. PubMed ID: 2787433
    [Abstract] [Full Text] [Related]

  • 15. Control of parathyroid function in patients with a short history of hemodialysis.
    Nishi H, Sato T, Kurihara T, Kurosawa T, Fukagawa M.
    Ther Apher Dial; 2005 Feb; 9(1):39-43. PubMed ID: 15828904
    [Abstract] [Full Text] [Related]

  • 16. Long-term effects of intravenous 1 alpha (OH)D3 combined with CaCO3 and low-calcium dialysis on secondary hyperparathyroidism and biochemical bone markers in patients on chronic hemodialysis.
    Brandi L, Daugaard H, Nielsen PK, Jensen LT, Egsmose C, Olgaard K.
    Nephron; 1996 Feb; 74(1):89-103. PubMed ID: 8883025
    [Abstract] [Full Text] [Related]

  • 17. Effect of administering calcium carbonate to treat secondary hyperparathyroidism in nondialyzed patients with chronic renal failure.
    Tsukamoto Y, Moriya R, Nagaba Y, Morishita T, Izumida I, Okubo M.
    Am J Kidney Dis; 1995 Jun; 25(6):879-86. PubMed ID: 7771484
    [Abstract] [Full Text] [Related]

  • 18. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V, Torregrosa V.
    Nefrologia; 2008 Jun; 28 Suppl 3():67-78. PubMed ID: 19018742
    [Abstract] [Full Text] [Related]

  • 19. Long-term effects of intravenous calcitriol therapy on the control of secondary hyperparathyroidism.
    Malberti F, Corradi B, Cosci P, Calliada F, Marcelli D, Imbasciati E.
    Am J Kidney Dis; 1996 Nov; 28(5):704-12. PubMed ID: 9158208
    [Abstract] [Full Text] [Related]

  • 20. [Oral pulsatile therapy with active vitamin D3 metabolites--an efficient method of parathyroid hormone synthesis suppression in uremic patients with severe hyperparathyroidism. A pilot study].
    Matuszkiewicz-Rowińska J, Niemczyk S, Bogdańska-Straszyńska B, Ostrowski K.
    Pol Arch Med Wewn; 1993 Feb; 89(2):95-101. PubMed ID: 8502602
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.